Eicosapentaenoic and docosahexaenoic acid-enriched high fat diet delays the development of fatty liver in mice by Nikulkumar, Soni et al.
Chalmers Publication Library
Eicosapentaenoic and docosahexaenoic acid-enriched high fat diet delays the
development of fatty liver in mice
This document has been downloaded from Chalmers Publication Library (CPL). It is the author´s
version of a work that was accepted for publication in:
Lipids in Health and Disease (ISSN: 1476-511X)
Citation for the published paper:
Nikulkumar, S. ; Nookaew, I. ; Sandberg, A. et al. (2015) "Eicosapentaenoic and
docosahexaenoic acid-enriched high fat diet delays the development of fatty liver in mice".
Lipids in Health and Disease, vol. 14(1),  pp. 74.
http://dx.doi.org/10.1186/s12944-015-0072-8
Downloaded from: http://publications.lib.chalmers.se/publication/220378
Notice: Changes introduced as a result of publishing processes such as copy-editing and
formatting may not be reflected in this document. For a definitive version of this work, please refer
to the published source. Please note that access to the published version might require a
subscription.
Chalmers Publication Library (CPL) offers the possibility of retrieving research publications produced at Chalmers
University of Technology. It covers all types of publications: articles, dissertations, licentiate theses, masters theses,
conference papers, reports etc. Since 2006 it is the official tool for Chalmers official publication statistics. To ensure that
Chalmers research results are disseminated as widely as possible, an Open Access Policy has been adopted.
The CPL service is administrated and maintained by Chalmers Library.
(article starts on next page)
Soni et al. Lipids in Health and Disease  (2015) 14:74 
DOI 10.1186/s12944-015-0072-8RESEARCH Open AccessEicosapentaenoic and docosahexaenoic
acid-enriched high fat diet delays the
development of fatty liver in mice
Nikul K Soni1, Intawat Nookaew2,3, Ann-Sofie Sandberg1* and Britt G Gabrielsson1Abstract
Background: Low hepatic content of n-3 PUFA has been associated with NAFLD in humans. Whether this is
associated with reduced dietary intake or increased turnover of these FA is not clear. We have here investigated the
effects of dietary fat quality on hepatic lipid storage and transcriptomics over time.
Aim: To investigate the effects of quality of fat in a high fat diet (HFD) over time on hepatic lipid storage and liver
transcriptomics.
Methods and Results: Male C57BL/6J mice were fed control, HFD-eicosapentaenoic acid (EPA)/ docosahexaenoic acid
(DHA) or HFD-corn oil diet for 8 or 12 weeks. Body weight, body composition, plasma and hepatic triglyceride contents
were measured. Hepatic transcriptomes were analysed by microarray followed by gene-set enrichment analyses. At
8 weeks, the HFD-corn oil mice had higher body weight and adipose depot mass than the HFD-EPA/DHA but there were
no differences at 12 weeks. Hepatic triglyceride content was lower in HFD-EPA/DHA fed compared with the
HFD-corn oil fed mice at both time-points. Enrichment analyses of the hepatic transcriptomes showed that
lipid/fatty acid biosynthesis; transport and homeostasis were lower in the HFD-EPA/DHA fed compared with
the HFD-corn oil fed mice. Genes encoding proteins associated to cytoplasmic lipid droplets were expressed
at higher levels in livers from the HFD-corn oil compared to HFD-EPA/DHA mice.
Conclusions: Dietary EPA and DHA counteracted development of HFD-induced fatty liver. The liver transcriptome
data implicate that the quality of dietary fat could modulate Ppar-related gene expression that in turn affects hepatic
lipid storage and maintenance of metabolic health.
Keywords: Diet, Liver triglycerides, Transcriptome, Lipid droplets, PparIntroduction
It is becoming more established that an increased lipid
content in the liver can be viewed as a driver of the
metabolic dysfunctions that are observed in obesity [1].
Non-alcoholic fatty liver disease (NAFLD) covers the
spectrum of liver damage from simple fatty liver to stea-
tohepatitis and cirrhosis [2]. About 70 % of subjects with
type 2 diabetes or the metabolic syndrome develop
NAFLD [3]. Further, a recent retrospective study showed
that subjects diagnosed with NAFLD or non-alcoholic
steatohepatitis (NASH) had reduced life expectancy due* Correspondence: ann-sofie.sandberg@chalmers.se
1Divisions of Food and Nutrition Science, Department of Biology and
Biological Engineering, Chalmers University of Technology, SE-41296
Gothenburg, Sweden
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(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/to an increased mortality of 69 % and 86 %, respectively,
primarily caused by cardiovascular disease [4].
It has been suggested that a high dietary intake of
sucrose/fructose, cholesterol and saturated fat can be asso-
ciated with NAFLD in humans [5, 6]. Whether reduced
dietary intake of n-3 fatty acids is related to NAFLD pro-
gression, and whether low hepatic n-3 levels are cause or
consequence of NASH is not clear. In this study, groups of
male C57BL/6J mice were fed either a control diet or two
almost identical high-fat diets (HFDs; 31.7 E% fat) with
only minor differences in fat quality. One was based on
corn oil (HFD-corn oil) and the other was enriched in the
n-3 PUFA eicosapentaenoic acid (EPA) and docosahexae-
noic acid (DHA; HFD-EPA/DHA). The amount of EPA and
DHA included in the diet was calculated from a previousle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Compositions of control, high fat diet (HFD)- EPA/DHA
(ED) and HFD-corn oil (CO)
Ingredient (g/100 g diet) Control HFD ED HFD CO
Protein Casein 22.2 25.6 25.6
Carbohydrates Sucrose 5.0 10.0 10.0
Corn starch 56.0 34.8 34.8
Cellulose 5.0 5.8 5.8
Fat Total 5.0 15.0 15.0
Corn oil 2.5 3.0 5.0
Coconut oil 2.5 10.0 10.0
EPAX oilsa 0 2.0 0
Mineralsb 2.0 2.5 2.5
Miconutrientsc 3.0 3.0 3.0
Choline bitartrate 1.6 2.0 2.0
Cholesterol 0 1.0 1.0
Methionine 0.2 0.3 0.3
Energy content (kJ/100 g) 1599 1752 1752
Protein E% 24 25 25
Carbohydrate E% 65 44 44
Fat E% 12 32 32
Fatty acid compositiond (mg/g diet)
C10:0 0.20 1.47 1.33
C12:0 2.37 7.58 7.72
C14:0 1.54 4.58 4.78
C16:0 1.90 3.44 3.59
C18:0 0.68 2.26 2.49
C18:1n-9 2.82 4.80 5.26
C18:2n-6 3.62 5.03 7.36
C18:3n-6 0.12 0.22 0.26
C20:5n-3 (EPA) 0.00 2.03 0.01
C22:6n-3 (DHA) 0.00 4.58 0.01
Sum SFA 6.70 19.33 19.91
Sum MUFA 2.82 4.80 5.26
Sum n-6 PUFA 3.74 5.26 7.62
Sum n-3 PUFA 0.00 6.61 0.02
aEPAX 1050, EPAX 6015
bCaCO3 (57.7 %); KCl (19.9 %); KH2PO4 (11.9 %); MgSO4 (10.4 %)
cCorn starch (98.22 %); Ca(IO3)2 (0.0007 %); CoCO3 (0.064 %); CuO (0.02 %);
FeSO4 (0.5 %); MnO2 (0.035 %); Na2MoO4 (0.001 %); NaSeO3 (0.0007 %); ZnO
(0.1 %); Vitamin A (0.013 %); B2 (Riboflavin-5-phosphate sodium; 0.027 %); B3
(0.1 %); B5 (Ca Pantothenate; 0.057 %); B6 (0.023 %); B7 (0.0007 %); B9
(0.007 %); B12 (0.00008 %); D3 (0.007 %); E (0.25 %); K (0.003 %)
dAnalyses were performed in triplicates and data obtained by Gas
chromatography mass spectroscopy
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HFDs had cholesterol added since previous research has
shown that the combination of high fat and cholesterol in
the diet is required to induce fatty liver in mice [9].
The aims of this study were to investigate the effects of
dietary EPA and DHA vs. corn oil in a HFD on hepatic tri-
glyceride storage in liver over time and to identify putative
mechanisms of action by transcriptomics.
Results
Diets
With the exception of fat sources, all diets were formulated
from the same sources of macro- and micronutrients enab-
ling the direct comparison of the different fat qualities as
the main effector across the diets. The control diet con-
tained 12 E% fat and the HFDs contained 32 E% fat. The
two HFDs differed as follows: the HFD-corn oil contained
11 E% of corn oil, with high linoleic acid content, and the
HFD-EPA/DHA diet contained 6 E% corn oil and 4 E%
EPA/DHA-enriched oils (Table 1). The content of EPA plus
DHA in the HFD-EPA/DHA diet was 8 g/kg and was based
on a herring-based diet we previously have used [7, 8]. The
amount of protein was increased in the HFDs to achieve
similar E%. The amount of sugar and corn starch was ad-
justed to accommodate the higher fat content in the HFDs.
Delayed body weight gain and adiposity in the
HFD-EPA/DHA mice
At 8 weeks, the HFD-corn oil mice had higher body
weight gain compared to both the control and the HFD-
EPA/DHA mice but there was no difference between
HFD-EPA/DHA and the control mice (Fig. 1a left panel).
However, the relative retroperitoneal white adipose tissue
(rpWAT) and epididymal white adipose tissue (epiWAT)
weights were higher in the HFD-corn oil mice compared
to both the control and to the HFD-EPA/DHA mice
(Fig. 1b and c, left panel). There were no differences in the
relative rpWAT and epiWAT weights between HFD-EPA/
DHA and the control mice.
At 12 weeks, there were no differences in body weight
gain between the HFD-EPA/DHA mice compared to mice
fed the other two diets (Fig. 1a, right panel). The HFD-
corn oil mice had higher body weight change than the
controls. The body fat, measured by Dual energy X-ray
absorptiometry (DXA), was higher in the HFD-corn oil
mice (30.6 ± 1.6 body fat %) compared with the controls
(19.3 ± 1.5 %; p = 0.001). The HFD-EPA/DHA mice (26.3
± 2.4 body fat %) did not differ from either the control or
the HFD-corn oil mice. In agreement with the DXA, the
relative rpWAT and epiWAT weights were higher in the
HFD-corn oil mice compared with the controls (Fig. 1b
and c, right panels). The relative rpWAT or epiWAT
weights from the HFD-EPA/DHA mice not differ from ei-
ther the control or the HFD-corn oil mice.Reduced hepatic triglyceride content in the
HFD-EPA/DHA mice
There were no effects on the relative liver weights (g/100 g
body weight) after the 8-week diet intervention (Table 2).
At 12 weeks, the relative liver weights were lower in the






































































































Fig. 1 Effects of 8 weeks (left panel) or 12 weeks (right panel) diet
with control diet (white bars). HFD-EPA/DHA (black bars) and HFD-corn
oil (grey bars): a) body weight change. b) rpWAT. c) epiWAT. d) Hepatic
triglyceride content. Data are shown as mean ± SEM; 8 weeks: n = 10.
12. 12; 12 weeks: n = 11. 12. 12; control. HFD-EPA/DHA. HFD-corn oil;
respectively. Different letters (e.g. a, b, c) denote significant difference
of p < 0.05 between groups as evaluated by the Tukey’s multiple
comparison test (see further the Methods section)
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differ from either HFD.
At 8 weeks, the HFD-corn oil mice had higher content
of hepatic total lipids compared to both HFD-EPA/DHA
and control mice (Table 2). At 12 weeks, the total
lipid content remained lower in the livers from the
HFD-EPA/DHA mice compared with the HFD-corn oil
mouse. There were no differences between the controls
and either HFD in total liver lipid content at 12 weeks.
After the 8-week diet intervention, the hepatic triglyceride
content in livers from the HFD-corn oil mice was ap-
proximately 1.7-fold higher than the control livers and
3-fold higher than the HFD-EPA/DHA livers (Fig. 1d,
left panel). Furthermore, the triglyceride content of the
HFD-EPA/DHA livers was about 0.5-fold of the con-
trol livers. The differences in hepatic triglyceride con-
tent in the HFD-corn oil and the HFD-EPA/DHA-fed
mice remained significant after 12 weeks (Fig. 1d, right
panel). The triglyceride content of the control livers
did not differ from either of the two HFDs after the
12 weeks diet intervention. The cholesterol content in
the liver did not differ between two HFDs but it was
higher in both HFDs compared to control at 8 and
12 weeks diet intervention (Table 2).
The plasma triglyceride concentrations were higher in
the HFD-EPA/DHA mice compared with the HFD-corn
oil mice after 8 weeks (Table 2). Neither HFD group dif-
fered from the control plasma triglyceride levels. There
were no differences in plasma triglyceride concentra-
tions after 12 weeks of dietary intervention. There
were no differences in plasma cholesterol concentra-
tions after 8 weeks but at 12 weeks the plasma levels
were higher in mice fed HFD-corn oil compared to
HFD-EPA/DHA and control.
Hepatic fatty acid composition
Neutral lipids
Table 3 shows amount of individual fatty acids of inter-
est in the hepatic neutral lipid fraction. The levels of sat-
urated fatty acid (SFA) C16:0 at 8 weeks were lower in
livers from the control and the HFD-EPA/DHA fed mice
compared to those fed HFD-corn oil. At 12 weeks, the
amount of C16:0 remained lower in the HFD-EPA/DHA
livers compared to the HFD-corn oil livers whereas the
controls did not differ from either. There were no differ-
ences in the levels of C18:0 after 8 weeks diet interven-
tion. The levels of C18:0 were lower in HFD-EPA/DHA
fed mice compared to HFD-corn oil at 12 weeks. The
MUFA content in livers from the HFD-corn oil mice
were much higher than that found in the control or
HFD-EPA/DHA livers at both 8 weeks and 12 weeks. As
expected, the levels of EPA (C20:5n-3) and DHA
(C22:6n-3) were higher in HFD-EPA/DHA fed mice at
both time points.
Table 2 Dietary effects on liver weight, plasma and hepatic lipid content
Parameter 8 weeks 12 weeks
Control HFD ED HFD CO Control HFD ED HFD CO
n 9 12 12 10 9 10
Liver (% Bw) 4.4 ± 0.5 4.5 ± 0.3 4.2 ± 0.2 4.6 ± 0.1ab 4.3 ± 0.1a 4.8 ± 0.1b
Hepatic total lipid (mg/g dry liver weight)a 4.6 ± 0.3a 3.9 ± 0.2a 6.9 ± 0.4b 5.2 ± 0.5ab 4.7 ± 0.3a 6.5 ± 0.5b
Plasma triglycerides (mmole/L) 0.9 ± 0.1ab 1.1 ± 0.1a 0.7 ± 0.0b 1.2 ± 0.1 1.0 ± 0.1 1.0 ± 0.1
Hepatic total cholesterol (mg/g dry liver weight) 5.0 ± 0.2a 6.2 ± 0.4b 6.0 ± 0.1b 4.4 ± 0.1a 6.4 ± 0.2b 6.4 ± 0.2b
Plasma total cholesterol (mmole/L) 5.6 ± 0.9 5.5 ± 0.8 5.4 ± 0.9 6.3 ± 0.3a 6.0 ± 0.3a 9.2 ± 0.5b
Data are shown as mean ± SEM; different letters show significant differences tested by ANOVA followed by Tukey’s multiple comparison test
aLipid measurements n = 7, 8, 8 for Control, HFD-EPA/DHA and HFD-corn oil, respectively. High fat diet (HFD)- EPA/DHA (ED) and HFD-corn oil (CO)
Table 3 Liver fatty acids profiles
8 week 12 week
Neutral Lipids Control HFD ED HFD CO Control HFD ED HFD CO
Sum SFA 15.5 ± 1.3 12.3 ± 2.0 26.3 ± 1.7 20.6 ± 2.5 15.6 ± 1.8 23.6 ± 1.3
C16:0 13.5 ± 1.2a 10.2 ± 1.5a 23.9 ± 1.6b 18.2 ± 2.3ab 13.8 ± 1.6a 21.2 ± 1.2b
C18:0 2.1 ± 0.1 2.1 ± 0.5 2.4 ± 0.2 2.3 ± 0.2ab 1.9 ± 0.2a 2.4 ± 0.1b
Sum MUFA 28.0 ± 3.3 11.0 ± 2.8 44.3 ± 3.5 37.1 ± 6.3 19.9 ± 3.5 49.6 ± 4.0
C16:1n-7 4.1 ± 0.5a 2.2 ± 0.6b 1.8 ± 0.2b 5.5 ± 0.9a 4.2 ± 0.7a 9.6 ± 0.7b
C18:1n-9 19.4 ± 2.1a 7.9 ± 1.9b 33.9 ± 2.6c 25.1 ± 4.4ab 13.9 ± 2.4a 31.7 ± 2.6b
C18:1n-7 4.5 ± 0.7a 0.9 ± 0.3b 8.5 ± 0.8c 6.5 ± 1.1a 1.7 ± 0.4b 8.2 ± 0.7a
Sum n-6 PUFA 9.4 ± 0.4 7.7 ± 1.3 14.9 ± 0.8 8.9 ± 1.0 7.9 ± 0.5 17.1 ± 0.9
C18:2n-6 6.9 ± 0.3a 6.8 ± 1.0a 14.9 ± 0.8b 7.2 ± 0.7a 7.9 ± 0.5a 14.9 ± 0.7b
C20:4n-6 2.4 ± 0.1a 0.9 ± 0.3b 0.0 ± 0.0c 1.7 ± 0.2a 0.0 ± 0.0b 2.2 ± 0.3a
Sum n-3 PUFA 0.0 ± 0.0 9.2 ± 1.5 0.0 ± 0.0 0.3 ± 0.0 11.5 ± 1.3 0.0 ± 0.0
C20:5n-3 (EPA) 0.0 ± 0.0a 1.6 ± 0.3b 0.0 ± 0.0a 0.0 ± 0.0a 2.3 ± 0.3b 0.0 ± 0.0a
C22:6n-3 (DHA) 0.0 ± 0.0a 7.6 ± 1.2b 0.0 ± 0.0a 0.3 ± 0.0a 9.3 ± 1.0b 0.0 ± 0.0a
Phospholipids
Sum SFA 19.4 ± 0.7 23.0 ± 1.2 17.1 ± 0.5 20.5 ± 0.5 21.7 ± 1.2 17.8 ± 1.0
C16:0 11.6 ± 0.4a 15.3 ± 0.7b 10.7 ± 0.3a 12.6 ± 0.3ab 14.7 ± 0.8b 11.2 ± 0.6a
C18:0 7.8 ± 0.3a 7.7 ± 0.5a 6.4 ± 0.2b 8.0 ± 0.2a 7.0 ± 0.4ab 6.6 ± 0.4b
Sum MUFA 7.2 ± 0.2 6.5 ± 0.4 6.40.2 7.5 ± 0.1 6.2 ± 0.3 6.3 ± 0.2
C16:1n-7 1.0 ± 0.0 0.9 ± 0.1 1.1 ± 0.1 0.9 ± 0.0 0.9 ± 0.1 1.0 ± 0.0
C18:1n-9 6.2 ± 0.2a 5.6 ± 0.3ab 5.3 ± 0.1b 6.6 ± 0.1a 5.4 ± 0.2b 5.3 ± 0.2b
Sum n-6 PUFA 21.2 ± 0.8 11.7 ± 1.1 19.8 ± 1.4 19.6 ± 0.8 11.7 ± 0.8 20.8 ± 0.9
C18:2n-6 6.0 ± 0.3 6.6 ± 1.0 6.2 ± 0.9 5.4 ± 0.2a 6.6 ± 0.5ab 7.7 ± 0.4b
C20:3n-6 1.2 ± 0.1a 0.4 ± 0.0b 2.0 ± 0.1c 1.2 ± 0.1a 0.6 ± 0.0b 1.7 ± 0.1c
C20:4n-6 13.9 ± 0.4a 4.7 ± 0.1b 11.6 ± 0.4c 13.0 ± 0.5a 4.6 ± 0.3b 11.3 ± 0.4c
Sum n-3 PUFA 3.5 ± 0.1 13.2 ± 2.0 2.8 ± 0.1 2.7 ± 0.2 12.4 ± 0.8 2.2 ± 0.1
C20:5n-3 (EPA) 0.0 ± 0.0a 0.4 ± 0.0b 0.0 ± 0.0a 0.0 ± 0.0a 0.4 ± 0.0b 0.0 ± 0.0a
C22:6n-3 (DHA) 3.5 ± 0.1a 12.7 ± 2.0b 2.8 ± 0.1a 2.7 ± 0.2a 12.4 ± 0.8b 2.2 ± 0.1a
Data are presented as mg/g dry liver weight and shown as mean±SEM. Different letter shows significant differences tested by ANOVA followed by Tukey's multiple comparison test
Liver fatty acid profiles n = 7, 8, 8 for Control, HFD ED and HFD CO, respectively. High fat diet (HFD)- EPA/DHA (ED) and HFD-corn oil (CO)
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Table 3 shows the fatty acid composition of the hepatic
phospholipid fraction. At 8 weeks, the phospholipid
C16:0 content was higher in livers from mice fed the
HFD-EPA/DHA compared to mice fed the other two di-
ets. Furthermore, the phospholipid C18:0 content was
lower in HFD-corn oil compared to other two diets,
whereas there was no difference in the C18:0 content
between the control and the HFD-EPA/DHA fed mice.
At 12 weeks higher amounts of C16:0 was present in
HFD-EPA/DHA fed mice compared to HFD-corn oil but
the amounts did not differ when compared to control.
Also, the HFD-corn oil fed mice had lower amounts of
C18:0 to control but did not differ from HFD-EPA/
DHA. There were no difference in the C16:1n-7 levels at
both time points whereas, the amounts of C18:1n-9 were
lower in HFD-corn oil fed mice compared to control at
8 weeks. Also, C18:1n-9 levels were higher in control
compared to HFD-EPA/DHA and HFD-corn oil at
8 weeks. There were no difference in C18:2n-6 content at
8 weeks but at 12 weeks higher levels was detected in
HFD-corn oil fed mice compared to control. The levels of
C20:4n-6 (arachidonic acid) was lower in HFD-EPA/DHA
compared to either diet at both the time points whereas
the levels of EPA and DHA were higher after the
HFD-EPA/DHA feeding.Time-dependent effects of high fat diet on hepatic pathways
Additional file 1: Figure S4a shows that the Gene Ontology
(GO) Biological Processes (BPs) that were upregulated by
both HFDs vs. control at 8 weeks mainly related to cell
cycle/DNA replication, fatty acid β-oxidation and protein
transport. Examples of BPs downregulated were choles-
terol, sterol or isoprenoid biosynthesis, and signalling via
G-protein coupled receptors (GPCR). At 12 weeks, the
BPs upregulated by both HFDs vs. control involved drug
metabolic processes, fatty acid metabolism and positive
regulation of sequestering of triglyceride (Additional file 1:
Figure S4b). BPs downregulated were cholesterol, sterol,
very long-chain fatty acid and lipid biosynthetic processes
and GPCR signalling pathways.Time-dependent effects of dietary fat quality on hepatic
pathways
Biological processes that were up- or downregulated
by HFD-EPA/DHA vs. HFD-corn oil at 8 and at
12 weeks are shown in Fig. 2. The BPs making up
cluster 1a and 1b showed little regulation at 8 weeks
but were upregulated by HFD-EPA/DHA at 12 weeks.
These clusters include processes like transcription
(histone methylation/acetylation; chromatin modification),
translation (mRNA/rRNA/tRNA processing, regulation of
translation) and protein turnover (polyubiquitination).Two BPs related to fatty acid β-oxidation were also
found here. Cluster 2a contained BPs downregulated by
HFD-EPA/DHA vs. HFD-corn oil at week 8 but not at
week 12. These BPs involved protein transport and
metabolism of lipids and fatty acids. Cluster 2b at the
bottom of the heatmap is composed of BPs downregu-
lated by HFD-EPA/DHA vs. HFD-corn oil at both time
points. These processes mainly involved lipid/sterol
metabolism, lipid and fatty acid biosynthesis, lipopro-
tein transport and cholesterol/phospholipid efflux.
Cluster 3 and 4 show BPs that were either not
affected or upregulated by HFD-EPA/DHA vs HFD-
corn oil at 8 weeks followed by downregulation at
12 weeks. Members of this cluster related to signaling
particularly via GPCR, chemotaxis or adhesion.
Time-dependent effects of diet on gene expression
Additional file 1: Figure S5a shows Venn diagram of the
differentially expressed transcripts at 8 weeks; HFD-EPA/
DHA vs. control (n = 1177), HFD-corn oil vs. control (n =
1288) and HFD-EPA/DHA vs. HFD-corn oil (n = 341).
After 12 weeks, corresponding numbers were: HFD-EPA/
DHA and control (n = 1370), HFD-corn oil vs. control
(n = 1066) and HFD-EPA/DHA vs. HFD-corn oil (n = 142.
The 89 transcripts in Additional file 1: Figure S5a that dif-
fered in both comparisons HFD-EPA/DHA vs. control and
in HFD-EPA/DHA vs. HFD-corn oil at 8 weeks plus the
12 transcripts that differed between all three comparisons
were further investigated (Fig. 3a). Corresponding gene
expression data of the 61 transcripts at 12 weeks is shown
in Additional file 1: Figure S6a, S6b and Fig. 3b show the
112 and 37 transcripts that were differentially regulated by
HFD-corn oil compared to the other two diets at 8 and
12 weeks, respectively. These figures demonstrate that
there is a clear time-dependence in that fewer genes were
differentially regulated by either HFD at 12 weeks.
Specific effects of HFD-EPA/DHA and of HFD-corn oil on
gene expression
The boxed-in areas in the heatmap in Fig. 3a show genes
that were downregulated by HFD-EPA/DHA compared
with the other two diets at 8 weeks. Figure 4 shows the
expression of some these genes at 8 weeks and 12 weeks.
The genes are coding for proteins involved in lipoprotein
particle assembly (ApoA4), fatty acid transport (Fabp2)
and biosynthesis of long-chain PUFA (Elovl2, Elovl5,
Fads1 and Fads2). ApoA5 was downregulated by HFD-
EPA/DHA at 8 weeks but not at 12 weeks. Examples of
genes that were upregulated by HFD-EPA/DHA compared
with the other two diets wereMt1 and Mt2.
The boxed-in areas in the heatmap in Fig. 3b show genes
that were upregulated by HFD-corn oil compared with the
other two diets at 8 weeks. Figure 5 shows expression of
genes that were upregulated by HFD-corn oil vs. both
Fig. 2 Heatmap of GO: BPs from the gene set enrichment analysis of transcriptome data from HFD-EPA/DHA vs HFD-corn oil comparisons at
8 weeks (left column) and 12 weeks (right column). Clusters 1a/b to 4 are shown and discussed in the text. The colour intensities show the level
of enrichment of each GO:BP term where blue signifies downregulated processes and red upregulated; FDR adjusted p-value <0.05
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Fig. 3 Heatmaps of individual gene expression that were regulated at 8 weeks by a) HFD-EPA/DHA and b) HFD-corn oil vs. the other two diets.
Not annotated (“NA”) transcripts were excluded. The signals were normalised row wise to 0 and are shown from blue to red colour signifying the
lowest to the highest gene expression values
Soni et al. Lipids in Health and Disease  (2015) 14:74 Page 7 of 13control and HFD-EPA/DHA at 8 weeks but did not differ
between the two HFDs at 12 weeks. These genes are known
to be regulated by Pparγ, several of which are associated to
cytoplasmic lipid droplet formation in hepatocytes (Cidea,
Cidec, Fitm1, Cd36, Aldh3a2).
The final Fig. 6 shows gene pattern that were upregulated
by HFD-EPA/DHA at 8 weeks vs. both control and HFD-
corn oil, and with similar expression pattern at 12 weeks.
These genes were Retsat, Slc22a5, Hsd17b6, Etnppl and
Mreg.
Discussion
The data presented in this study show that mice fed the
EPA/DHA-enriched HFD were metabolically healthierthan the HFD-corn oil mice despite similar degree of
adiposity at 12 weeks. The metabolic health was expressed
as the lower hepatic triglyceride levels in the mice fed
HFD-EPA/DHA compared to the HFD-corn oil fed mice
at both the time points. Transcriptomics analyses revealed
that expression of genes coding for proteins associated to
lipid droplets in hepatocytes were upregulated in the
HFD-corn oil livers consistent with increased lipid storage.
In contrast, Pparα-related gene expression was upregu-
lated by the EPA/DHA-enriched diet suggestive of in-
creased usage of lipids as fuel.
EPA and DHA enriched diets have been shown to
reduced the risk of metabolic syndrome [10]. The fatty acid
profile of diets shows that HFD-EPA/DHA diet provided a
Fig. 4 Expression of genes coding for proteins involved in lipid
metabolism that were downregulated by HFD-EPA/DHA (black bars)
vs. both control (white bars) and HFD-corn oil (grey bars). Results from
8 weeks (left panels) and 12 weeks (right panels) are shown. a) ApoA4.
b) Fabp2. c) Elovl2. d) Elovl5. e) Fads1 and f) Fads2. Gene expression
(GE) from normalized microarray data and are shown in arbitrary units
as mean ± SEM. FDR adjusted p-values p < 0.05; * vs. control.
§ vs. HFD-EPA/DHA
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was present in the neutral lipid fraction. The mice fed the
HFD-corn oil diet showed instead an excess of MUFA and
n-6 PUFA storage in the hepatic triglycerides. Whether this
difference in fatty acid profiles as a result of the two HFD is
directly related to the much lower hepatic triglyceride con-
tent in the HFD-EPA/DHA mice than in the HFD-corn oil
mice remains to be elucidated. Similar to our study, others
have shown that dietary fish oil or EPA/DHA in HFDs
counteracts lipid storage in livers of C57BL male mice
[11–13]. One explanation to the lower liver triglyceride
content after the HFD-EPA/DHA feeding could be upreg-
ulation of fatty acid β-oxidation since this is normally the
major pathway to dispose excess fatty acid in the liver [2].
This is in line with the finding that C57BL mice fed HFD
enriched in fish oil had lower level of hepatic steatosis and
increased energy expenditure [14]. Alternatively, it
has been shown that the n-6:n-3 ratio was increased
in fatty livers from patients undergoing bariatric sur-
gery [15]. This could be either caused by the increased n-
6:n-3 ratio common in present day diets or the increased
ratio could be a sign of inflammation in the liver, causing
consumption of n-3-PUFA [16]. In the present study, the
ratio of n-6:n-3 in the three diets were 1:62, 1:2.1 and 1:64
(control, HFD-EPA/DHA and HFD-corn oil, respectively).
This may have bearing on as to why the triglyceride con-
tent at 8 weeks was lower in livers from the HFD-EPA/
DHA mice even when compared to the controls.
The DXA-measurements performed at 12 weeks were
consistent with the epiWAT and rpWAT relative weights.
We can therefore assume that the HFD-EPA/DHA mice
also had lower body fat % compared HFD-corn oil after
8 weeks diet intervention. This is in agreement with a pre-
vious study showing that male C57BL mice fed a high fat/
high sucrose diet containing 5 wt.% EPA for 20 weeks had
lower white adipose tissue depots weight than those fed
the same diet but without EPA [17]. The dose of EPA and
DHA used in this study, 0.83 wt.%, was much lower which
may explain why the HFD-EPA/DHA mice in this study
increased in adiposity after 12 weeks diet intervention. In
addition, a lower hepatic triglyceride content has previ-
ously been shown to associate with lower epiWAT weight
in C57BL mice fed HFD with EPA/DHA [12].
The family of Ppar transcription factors are widely
believed to be primary mediators of the effects of EPA
and DHA. These transcription factors regulate several
lipid metabolic pathways in liver, adipose tissues and
skeletal muscle. In obese humans with NAFLD, hepatic
PPARG expression was upregulated [18]. Activation of
Pparα reduces lipid storage in liver by promoting fatty
acid β-oxidation [2]. In mice, Pparg overexpression in-
duced hepatic steatosis whereas its disruption improved
fatty liver [19]. The elevated Pparg gene expression at
8 weeks in the HFD-corn oil livers could directly
Fig. 5 Expression genes coding for proteins involved in lipid droplet assembly or associated to lipid droplets in the cell upregulated by HFD-corn
oil (grey bars) vs. both control (white bars) and HFD-EPA/DHA (black bars). Results from 8 weeks (left panels) and 12 weeks (right panels) are
shown. a) Pparg. b) Cidea. c) Cidec. d) Fitm1. e) Cd36. f) Aldh3a2. g) Lgals1 and h) Sema5b. Gene expression (GE) from normalized microarray data
and are shown in arbitrary units as mean ± SEM. FDR adjusted p-values p < 0.05; * vs. control. § vs. HFD-EPA/DHA
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livers. In contrast, there was no difference in hepatic
Pparg gene expression in HFD-corn oil and HFD-
EPA/DHA mice at 12 weeks. This could be an early
sign of developing hepatic steatosis in HFD-EPA/DHA
mice since Pparγ activation triggers a signalling cascade
contributing to the formation of lipid droplets in the cyto-
plasm. Cidec (a.k.a. Fsp27), which was upregulated in the
mice fed HFD-corn oil at 8 weeks, was regulated by Pparγ
in steatotic livers from ob/ob mice [20]. However, in lean
mice Cidec is regulated by Pparα, and recent research
showed that simultaneous activation of Pparα and silen-
cing of Cidec protected diet-induced obese mice from
hepatic steatosis [21]. Other genes that are associated to
LD formation, Cidea and Fitm1 were also expressed at
higher levels at 8 weeks in the HFD-corn oil livers com-
pared to livers from the other two diets. Cidea is usually
expressed at low levels in mouse liver but can be induced
by treatment with Pparα agonists or by Pparγ overexpres-
sion [9]. Overexpression of Fitm1 induced LD formationin vivo in mouse liver [22]. Cd36 is also regulated by
Pparγ and, although not directly associated with LD, in-
creased hepatic Cd36 expression with age was recently
shown to be associated with increased susceptibility to
NAFLD [23]. The other gene transcripts such as Aldh3a2,
Lgals, and Sema5b were also upregulated in HFD-corn oil
mice as compared to HFD-EPA/DHA and control at
8 weeks. Aldh3a2 could also be involved in the formation
of LD as Aldh3b2 was recently shown to be a LD-
associated protein [24]. It appears therefore that induction
of these genes, most likely through Pparγ, precedes the in-
creased triglyceride storage in liver caused by a HFD. In-
teresting, LD proteins were suggested as drug targets for
treatment of NAFLD [25].
The expression of the gene cluster including RetSat was
upregulated by HFD-EPA/DHA vs. control and HFD-corn
oil fed mice at one or both time-points, and had similar
expression pattern at the other time-point. This cluster
may therefore represent putative mechanisms to under-
stand how EPA/DHA maintains lower hepatic triglyceride
Fig. 6 Expression genes upregulated by HFD-EPA/DHA vs. control
and HFD-corn oil at 8 weeks (left) or at 12 weeks (right): a)
Retsat. b) Slc22a. c) Hsd17b6. d) Etnppl. e) Mreg. Gene expression
(GE) from normalized microarray data and are shown in arbitrary
units as mean ± SEM. FDR adjusted p-values p < 0.05; * vs. control.
§ vs. HFD-corn oil
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bers have two obvious commonalities. The first is that,
two of them are regulated by Pparα. In hepatocytes,
RetSat (a.k.a. Ppsig) is directly regulated by Pparα [26],
where it converts retinol to all-trans-13,14-dihydro-retinol[27]. Slc22a5 is also known to be regulated by Pparα and
is coding for a plasma membrane carnitine transporter,
which is an essential metabolite required for mitochon-
drial β-oxidation of fatty acids [28]. However, there were
no dietary effects on Ppara transcript levels at either
time-point (data not shown). The other common
theme is that two genes are associated to Vitamin A
metabolism; Retsat and Hsd17b6. Similar to RetSat,
Hsd17b6 is also involved in retinoid metabolism [29].
However, Ppars form heterodimers with the retinoic acid
X receptor (Rxr) and 9-cis retinoic acid is the most potent
ligand of Rxr, with 40 times the affinity to the receptor
compared with trans-retinols [30]. Induction of Retsat
may therefore result in modification of Ppar-Rxr signal-
ling. Alternatively, a recent paper on bioinformatics ana-
lysis of public microarray data identified Retsat as a key
component in disorders relating to insulin resistance
in both mice and humans [31], a condition strongly
associated to NAFLD. This suggests that Retsat per se is
of high relevance in NAFLD. Etnppl and Mreg were other
genes that showed similar pattern to that of Retsat but lit-
tle is known about these two genes and their involvement
in hepatic function. The human homolog of Etnppl
catalyse the catabolism of phosphoethanolamine [32] and
Mreg is involved in biogenesis of melanosomes, a
lysosome-like organelle in retinal epithelial cells and
melanocytes [33].Conclusion
The data presented here show that EPA and DHA delayed
the development of liver dysfunction in mice despite the
catch-up in adiposity at 12 weeks. Further, the quality of
dietary fat affected transcriptional programs initiated by
Ppars differently as reflected by the gene-set enrichment
analyses. The corn oil-based HFD induced Pparγ gene sig-
natures, the EPA/DHA-enriched HFD induced genes
known to be regulated by Pparα. In addition, the EPA/
DHA-enriched diet also induced Retsat expression that
may affect the Ppar system through the regulation of ago-
nists to the Rxr heterodimer.Methods
Animals and study design
The Animal Ethics Committee at the University of
Gothenburg, Sweden, approved the study (Dnr: 253–2009).
Six-week old C57BL/6J male mice (Harlan Laboratories,
Netherlands) were housed in temperature and humidity
controlled environment with 12 h light/dark cycle at our
local animal facility. The mice were caged 5–6 per groups
with ad-libitum access to water and chow. The number of
animals per diet in each study was 12 per group initially.
There were no differences in body weights at the start of
the experiments. The body weights were recorded weekly.
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12-week study, respectively. Two mice from the control
group in the 8-week study were removed due to fighting.
In the 12-week experiment, the HFD-EPA/DHA group
started with 11 animals and tissues from two animals from
each group were perfused with saline for histochemistry
and therefore excluded in the analyses.
The food was removed at 6 am and the mice were
killed on three consecutive days between 9 am and
12 am by lethal intraperitoneal injections of sodium
pentobarbital. Animals were selected randomly and al-
ternatively from two diet groups each day. Blood was
collected from the heart followed by cervical dislocation.
Plasma was obtained by centrifugation at 4 °C of EDTA
whole blood (10 min; 10,000 x g). Tissues were dissected
out, weighed and frozen in liquid nitrogen. Tissues and
plasma were stored at −80 °C.
Diet composition
The EPA and DHA-enriched oils (EPAX 1050 and EPAX
6015) were a gift from EPAX AS (Lysaker, Norway; now
part of the FMC Corporation, Pennsylvania, USA). Table 1
shows the diet compositions; the control diet provided 24
Energy % (E%) of protein, 12 E% of fat and 65 E% of car-
bohydrates, whereas the two HFD contained 25 E% of
protein, 32 E% of fat and 44 E% of carbohydrates. The di-
ets were prepared by Lantmännen (Kimstad, Sweden) and
were delivered in powdered form. Therefore, the pow-
dered diet and water was rolled into balls to make the
texture more appealing to the mice when the diet was
changed three times per week.
Body composition
Retroperitoneal and epididymal white adipose tissues
(rpWAT and epiWAT, respectively) were dissected out
and weighed in both the 8 and the 12-week diet inter-
vention study.
At 12 weeks, the mice were anesthetized with isofluor-
ane (Baxter, IL, USA) on the day of termination and
body composition was measured by Dual energy X-ray
Absorption (DXA) using a Lunar PIXImus densitometer
(Lunar Corp, WI, USA) as previously described [34].
Isolation of total RNA and microarray analysis
Four mice were selected from each diet group on the
basis of body weight, plasma triglyceride and plasma
cholesterol levels. Total RNA from the livers was
purified using the RNeasy Lipid Tissue Mini kit (Qiagen
Nordic, Sollentuna, Sweden) according to the manufac-
turer’s instruction. Total RNA concentrations were
measured using the NanoDrop 2000c UV–vis Spectropho-
tometer (Thermo Fisher Scientific, Gothenburg, Sweden).
The RNA quality of samples were evaluated using the RNA6000 Nano LabChip for Agilent 2100 Bioanalyzer (Agilent
Technologies, Gothenburg, Sweden).
The RNA was labelled and hybridized to GeneChip®
Mouse Gene 2.0 ST arrays (Affymetrix, CA, USA) at the
SCIBLU Genomics core facility (Swegene Centre for
Integrative Biology at Lund University, Sweden). The
raw data is deposited in Gene Expression Omnibus data-
base under accession number GSE65370.
Data acquisition and analysis
The CEL files were imported to the window based Affy-
metrix® Expression Console™ software 1.3 for background
correction and signal estimation from microarrays. The
microarray data was normalized applying the iter-Probe
Logarithmic Intensity Error algorithm together with the
quantile normalization and perfect match probe only
methods (Fig. 6). Empirical Bayes method from the limma
package was then applied to the signals to calculate mod-
erated t- and F-statistics, log odds and differential
expression for comparisons between diets. Based on
hierarchical clustering and scatter plots, one micro-
array from the HFD-corn oil group at 8 weeks was
removed from subsequent analyses (Additional file 1:
Figures S2-S3). The Piano package was used for Gene
Set Enrichment Analysis (GSEA) to identify the total
number of genes regulated and the direction of regu-
lation [35]. Gene Ontology (GO) terms were anno-
tated to each probe-set after performing GSEA. The
reporter algorithm was used to analyse the functional en-
richment level of individual GO term [36]. Heatmaps were
generated using the -log10p-values to visualize enriched
GO biological processes (BPs) terms.
Analysis of plasma and liver lipids
Plasma total triglyceride and cholesterol was determined
enzymatically with Konelab Autoanalyser version 2.0 at
the Clinical Chemistry department, Sahlgrenska University
Hospital, Gothenburg, Sweden.
Approximately 0.3 g of the livers were weighed and
freeze-dried overnight. The freeze-dried livers were
weighed again followed by lipid extraction using the Folch
method [37]. Briefly, 5 ml chloroform: methanol (2:1 v/v)
was added to each sample and mixed followed by 15–20
min ultrasonication at 40 Hz (Branson 8510, Branson
Ultrasonics Corp, CT, US). One ml of physiological saline
was added, mixed and centrifuged at 1700 × g in swing-
out buckets for 5 min. The lower organic phase was taken
off and kept, while the remainder was re-extracted with
1.5 ml chloroform: methanol. The two extracted organic
phases were combined and evaporated under a flow of ni-
trogen and redissolved in 5 ml isopropanol. The samples
were stored at −80 ° C until analysis. Hepatic triglyceride
content was measured in the total lipid fraction using
enzyme assay obtained from Sigma-Aldrich.
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Lipid classes were separated using solid phase extraction
(SPE) according to [38] Phospholipid (C17:0) and trigly-
ceride (C19:0) standards were added from the beginning.
Briefly, the aminopropyl solid phase extraction columns
were activated with 4 ml of hexane and then loaded with
1 ml of extracted liver lipids samples. Neutral lipids were
eluted with chloroform/isopropanol (2:1); free fatty acids
were eluted using diethylether/2 % acetone and phospho-
lipids were eluted with methanol and evaporated under
N2 stream. The samples were then methylated with 1 ml
10 % acetyl chloride in methanol/ 1 ml toluene and incu-
bated overnight. By adding 0.3 ml water and 4 ml petrol-
eum ether two phases were separated and the upper phase
was pipetted carefully, evaporated under nitrogen stream
and redissolved in 250 μl isooctane [39].
For lipid analysis of diets approximately 100 mg of finely
ground freeze-dried diet was used. Lipid extraction using
Folch method [37], separation of lipid classes and methy-
lation was performed as described above. The methyles-
ters were separated by gas chromatography (Agilent
7890A, Santa Clara, CA) and detected with mass spectros-
copy. Chemstation software (Agilent Technologies, Santa
Clara, CA) was used for evaluation. The samples were
separated on a VF-WAX (30mx0.25x0.25 um dF) column
(J&W Scientific, Folsom, CA) and quantified by electron
ionization with a 5975C inert XLK EI/CI MSD with a
triple-axis detector (Agilent Technologies).
Statistical analysis
Changes in body weights, body composition, adiposity
and blood and hepatic lipid data were tested by ANOVA
followed by Tukey-honest significant difference test
(Tukey-HSD) post-hoc tests. A p-value <0.05 was consid-
ered statistically significant. All statistical and microarray
data analysis were performed with the help of R Studio
software (Version 0.98.953 – © 2009–2013 RStudio, Inc.)
and required Bioconductor packages. For the microarray
data false discovery rate (FDR) adjusted p-values were
calculated and FDR adjusted p < 0.05 was considered
significant. All data are presented as mean ± SEM.Additional file
Additional file 1: Figure S1. Box and Wisker plots of the normalized of
hepatic transcriptome log2 values showing boxes of 25th, 50th and 75th
percentile and 10th and 90th. Figure S2. Dendogram of the hepatic
transcriptome array data by unsupervised clustering. The scale on the left
vertical bar is based on ward distance: a) unsupervised clustering of all
arrays. b) Distribution of all arrays by unsupervised clustering of the
microarray data after removing array HFDCO_8w_5592. Figure S3.
Scatterplots of all microarray data to visualize the variation between the
samples within each diet group: a) control diet. b) HFD-EPA/DHA diet. c)
HFD-corn oil diet and d) 8 week HFD-corn oil with data from one microarray
excluded (5592). Figure S4. Heatmaps showing results obtained from gene
set enrichment analysis (GSEA) of hepatic transcriptome data comparingboth the HFDs against control at 8 and 12 week diet intervention.
Not annotated (“NA”) transcripts were excluded. The signals were
normalised row wise to 0 and are shown from blue to red colour
signifying the lowest to the highest gene expression values. Figure S5.
Venn diagrams of number of genes that were significantly (adjusted
p-value < 0.05. FDR) changed irrespective of direction after a) 8 weeks
and b) 12 weeks of diet intervention. Figure S6. Heatmaps of genes
regulated by a) HFD-EPA/DHA or b) HFD-corn oil at 12 weeks.
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